Today We Are Closer To Measurably Improving Patient Lives

When I was 12 years old, I came home from school to learn that my father was diagnosed with a rare form of cancer. Later in life, I learned he had been misdiagnosed, and if it wasn’t for his gut feeling that the doctor was wrong, he wouldn’t be here with us today.

When it comes to their health, Americans don’t ask for second opinions enough. According to a poll from Harvard Medical School, 70% feel they don’t need to. If Americans aren’t compelled to get second opinions, we need to improve the initial care they receive. But how?

I dedicated the last decade to this charge. I got hands-on with clinical data and Memorial Sloan Kettering, built industry-first healthcare technology at DeepIntent, and strategized solutions to measurably improve patient lives.

Today, I have the answer.

It brings me great pleasure to announce the official launch of DeepIntent’s Patient Modeled Audiences. Our brilliant team of strategists, engineers, and data scientists have succeeded in developing a privacy-first, artificial intelligence (AI) solution that connects patients with the important and timely information they need to make better decisions about their health.

Patient Modeled Audiences combines emerging privacy technologies—like differential privacy—with artificial intelligence to build powerful advertising audiences based on social determinants. These precise, HIPAA-certified patient audiences have been rigorously tested in a closed beta that included a diverse cross-section of therapeutic categories and campaign goals. Our approach has been recognized by all 10 client participants as being a top performer —and in most cases, the best performer—among dozens of competing solutions.

In one case study, our audience placed 1st among 12 other data providers, yielding 25% higher Audience Quality and almost 60% higher efficiency on cost-per-treating-patient.

These results prove that the balance between privacy and performance is not zero-sum. With DeepIntent’s technology at the foundation, critical insights can be extracted from sensitive data while ensuring the utmost patient privacy. In turn, our clients will better identify patients in need, and share information that will drive better health outcomes.

This endeavor represents the hard work of various teams within DeepIntent and across our strategic partners. Collectively, we committed more than a year to design, implement, and certify Patient Modeled Audiences. Today is a significant victory—not just for our company and our partners, but for patients. When we arm patients with the information they need to make informed decisions about their health, we will save lives.

Share this Post

Related Articles

Pharmaceutical advertising is a critical part of the information landscape for today’s healthcare providers (HCPs). According to a study conducted by MAGNA Media Trials and DeepIntent, 92% of doctors say pharma ads increase awareness and drive meaningful conversations with their patients. This receptivity presents a major opportunity for healthcare brands to deepen their impact, and […]

As upfront season kicks off, media buyers across industries are recalibrating their video strategies, determining both how much to spend and where to spend it. For pharmaceutical marketers, that charge increasingly leads to connected TV (CTV). At AdLab 2025, marketing leaders took the stage to share how CTV is reshaping their media plans. Jeff Collins, […]

In a vibrant session at AdLab 2025, a panel of industry leaders explored how endemic publishers are adapting to a rapidly evolving programmatic landscape. The discussion featured Damon Basch, VP and Head of Digital Media at Veradigm; Tom Carr, SVP of Media and Data Strategy at Everyday Health; Francis D’Hondt, SVP of Addressable Health at […]

Never Miss New Insights

Sign up for the newsletter to ensure our latest whitepapers, research reports, and more are delivered to your inbox.